|
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
RECRUITINGPhase 2Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.
Actively Recruiting
PhasePhase 2
SponsorShenyang Sunshine Pharmaceutical Co., LTD.
Started2026-07-31
Est. completion2027-06-30
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07646626
Summary
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: * Males and/or females over age 18 * Histologically and/or cytologically documented local advanced or metastatic Colorectal adenocarcinoma (CRC), Urothelial Cancer (UC), Breast Cancer (BC), Biliary Tract Carcinoma(BTC), Gastric/Gastroesophageal Junction Cancer (G/GEJC) , etc. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Expected survival \>3 months. * Signed informed consent form. Exclusion Criteria: * Any remaining adverse events (AEs) \> grade 1 from prior anti-tumor treatment as per Common Terminology Criteria for Adverse Events(CTCAE) v6. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity. * Pregnant or nursing women or women/men who are ready to give birth * symptomatic central nervous system metastasis. * Allergy to other antibody drugs or any excipients in the study drugs. * Inadequate organ or bone marrow function. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Conditions2
CancerLocally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions3
Related trials
- A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors — Shenyang Sunshine Pharmaceutical Co., LTD.
- A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors — Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors — Shenyang Sunshine Pharmaceutical Co., LTD.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorShenyang Sunshine Pharmaceutical Co., LTD.
Started2026-07-31
Est. completion2027-06-30
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07646626